2024
Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling
Zarif T, Meador C, Qiu X, Seo J, Davidsohn M, Savignano H, Lakshminarayanan G, McClure H, Canniff J, Fortunato B, Li R, Banwait M, Semaan K, Eid M, Long H, Hung Y, Mahadevan N, Barbie D, Oser M, Piotrowska Z, Choueiri T, Baca S, Hata A, Freedman M, Berchuck J. Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling. Clinical Cancer Research 2024, 30: 3798-3811. PMID: 38912901, PMCID: PMC11369616, DOI: 10.1158/1078-0432.ccr-24-0466.Peer-Reviewed Original ResearchConceptsEGFR mutant lung adenocarcinomaSmall cell lung cancerSmall cell transformationLung cancer patient-derived xenograftPatient-derived xenograftsLung adenocarcinomaEGFR mutantsChIP-seqEpigenomic featuresMeDIP-seqImmunoprecipitation sequencingCell transformationHistological transformation to small cell lung cancerTransformation to small cell lung cancerMethylated DNA immunoprecipitation sequencingTransposase-accessible chromatin sequencingH3K27ac ChIP-seqMechanisms of treatment resistanceChromatin immunoprecipitation sequencingHistone modification H3K27acMutant lung adenocarcinomaCell lung cancerChromatin accessibilityChromatin sequencingEpigenomic landscape
2018
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Journal Of Thoracic Oncology 2018, 13: 1884-1896. PMID: 30267840, PMCID: PMC6251746, DOI: 10.1016/j.jtho.2018.09.012.Peer-Reviewed Original ResearchConceptsPD-L1 expressionPD-L1TIL activationHigh PD-L1 levelsDeath ligand 1 (PD-L1) expressionActivation statusKRAS wild-type tumorsKRAS mutantEGFR mutantsHigh PD-L1Multiplexed quantitative immunofluorescenceUnique immune profilePD-L1 levelsLigand 1 expressionDeath-1/EGFR-mutant tumorsImmunotherapy response ratesKRAS mutant tumorsWild-type tumorsHigher CD4NSCLC patientsImmune profileClinical efficacyKRAS WTLymphocyte populations
2017
Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations.
Toki M, Mani N, Smithy J, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Syrigos K, Rimm D. Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations. Journal Of Clinical Oncology 2017, 35: 9076-9076. DOI: 10.1200/jco.2017.35.15_suppl.9076.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorPD-L1 expressionPD-L2 expressionPD-L1Stroma expressionTIL activationKRAS mutantPD-1/PD-L1 axis inhibitorsMutation statusResponse rateProximity ligation assayHigh PD-L1 levelsActivation statusProgrammed Death Ligand 1EGFR mutantsHigh PD-L1NSCLC patient tumorsTherapy response ratesPD-L1 levelsDeath ligand 1Cell lung cancerEGFR-mutant tumorsPD-L1 tumorsHigh response rateMET amplification (amp) as a resistance mechanism to osimertinib.
Piotrowska Z, Thress K, Mooradian M, Heist R, Azzoli C, Temel J, Rizzo C, Nagy R, Lanman R, Gettinger S, Evans T, Hata A, Shaw A, Sequist L. MET amplification (amp) as a resistance mechanism to osimertinib. Journal Of Clinical Oncology 2017, 35: 9020-9020. DOI: 10.1200/jco.2017.35.15_suppl.9020.Peer-Reviewed Original Research
2016
PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Gettinger S, Politi K. PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? Clinical Cancer Research 2016, 22: 4539-4541. PMID: 27470969, PMCID: PMC5653962, DOI: 10.1158/1078-0432.ccr-16-1401.Peer-Reviewed Original Research
2012
Occupy EGFR
Park JH, Lemmon MA. Occupy EGFR. Cancer Discovery 2012, 2: 398-400. PMID: 22588876, PMCID: PMC3354646, DOI: 10.1158/2159-8290.cd-12-0144.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor (EGFR) mutationsNon-small cell lung cancer (NSCLC) tumorsCell lung cancer tumorsDifferent EGFR mutationsTreatment of glioblastomaLung cancer tumorsDistinct receptor conformationsEGFR mutationsReceptor mutationsEGFR inhibitorsCancer tumorsInhibitor efficacyEGFR mutantsEGFR variantsEGFRGlioblastomaDrug selectivityReceptor conformationNew studiesBarkovichErlotinibGefitinibTumors
2007
Ligand-Induced Structural Transitions in ErbB Receptor Extracellular Domains
Dawson JP, Bu Z, Lemmon MA. Ligand-Induced Structural Transitions in ErbB Receptor Extracellular Domains. Structure 2007, 15: 942-954. PMID: 17697999, DOI: 10.1016/j.str.2007.06.013.Peer-Reviewed Original ResearchConceptsExtracellular regionDimerization siteLow-resolution molecular envelopeEpidermal growth factor receptor (EGFR) activationGrowth factor receptor activationAutoinhibitory intramolecular interactionMajor domain rearrangementsSmall-angle X-ray scatteringReceptor extracellular domainDomain rearrangementsEGF receptorExtracellular domainLigand bindingEGFR mutantsReceptor conformationMutantsMolecular envelopeExtended conformationNew insightsReceptor activationCrystallographic studiesConformationIntramolecular interactionsReceptorsX-ray scattering
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply